小分子EGFR-TKIs在非小细胞肺癌治疗中的研究进展

Research Advances of Small Molecule EGFR-TKIs in NSCLC

小分子表皮生长因子受体酪氨酸激酶抑制剂(epithelial growth factor receptor tyrosine kinase in-hibitor, EGFR-TKI)在治疗伴有EGFR突变的非小细胞肺癌(non-small cell lung cancer, NSCLC)中获得了巨大的临床收益。但患者经过一段时间EGFR-TKIs治疗,不可避免的出现获得性耐药。本文主要对小分子EGFR-TKIs在NSCLC治疗中的研究进展及进行综述,为该类药物的临床使用及未来的研究方向提供参考。

Small molecule epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has achieved great clinical benefits in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation. However, after a period of EGFR-TKIs treatment, patients will inevitably acquire drug resistance. Thereview summarizes the research progress of EGFR-TKIs in the treatment of NSCLC which will provide reference for the clinical application and the future of EGFR-TKIs discovery.